WZ4002

Catalog No.S1173 Batch:S117303

Print

Technical Data

Formula

C25H27ClN6O3
Molecular Weight 494.18 CAS No. 1213269-23-8
Solubility (25°C)* In vitro DMSO 40 mg/mL (80.94 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
30%PEG400 0.5%Tween80 5%propylene glycol
30.0mg/ml Taking the 1 mL working solution as an example, add 300 μL of 100 mg/ml clarified PEG400 stock solution to 5 μL of Tween80, mix evenly to clarify it; add 50 μL Propylene glycol to the above system, mix evenly to clarify it; then continue to add 645 μL ddH2O to adjust the volume. to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM in BaF3 cell line; does not inhibit ERBB2 phosphorylation (T798I).
Targets
EGFR (L858R) [1]
(BaF3 cells)		 EGFR (L858R/T790M) [1]
(BaF3 cells)
2 nM 8 nM
In vitro WZ4002 inhibits other EGFR genotypes E746_A750 and E746_A750/T790M with IC50 of 2 and 6 nM. Besides, WZ4002 suppresses widetype ERBB2 with an IC50 of 32 nM. WZ4002 inhibits EGFR, AKT and ERK1/2 phosphorylation in NSCLC cell lines and WZ4002 prevents of EGFR phosphorylation in NIH-3T3 cells expressing different EGFR T790M mutant alleles. For WZ4002, kinases that exhibited greater than 95% inhibition relative to the DMSO control at 10 μM are selected for measurement of their dissociation constants. WZ4002, which possesses an ortho-methoxy group at the C2-aniline substituent, is more selective for EGFR compared to WZ3146. WZ4002 is 100-fold less effective at inhibiting phosphorylation of WT EGFR compared to the quinazoline inhibitors. Similarly, WZ4002 prevents EGFR kinase activity of recombinant L858R/T790M protein more potently than of WT EGFR, while the opposite is observed with HKI-272 and gefitinib. [1] In addition, the phosphorylated EGFR of Src TKI-resistant H1975 cells, as well as HCC827 cells, is completely suppressed by the third generation EGFR TKI, WZ4002. [2]
In vivo In a 2-week efficacy study, WZ4002 treatment results in significant tumor regressions compared to vehicle alone in both T790M containing murine models. [1] Treatment with low-dose WZ4002, and high-dose WZ4002 leads to mean decreases in tracer uptake of 26%, and 36%, respectively. [3]

Protocol (from reference)

Kinase Assay:[1]
  • EGFR kinase assays

    In vitro inhibitory enzyme kinetic assays using recombinant EGFR L858R/T790M and WT protein and are performed using the ATP/NADH coupled assay system in a 96-well format. WZ4002 is added to determine its inhibitory effects.

Cell Assay:[1]
  • Cell lines

    NSCLC, Ba/F3 cells, NIH-3T3 cells, PC9GR4 cells

  • Concentrations

    0-1 μM

  • Incubation Time

    72 hours

  • Method

    The NSCLC, Ba/F3 cells, NIH-3T3 cells, PC9GR4 cells are used and verified to contain EGFR delE746_A750/T790M by direct sequencing. Cell proliferation and growth assays are performed using the MTS assay. Site directed mutagenesis is performed using the Quick Change Site-Directed Mutagenesis kit.
Animal Study:[1]
  • Animal Models

    EGFR-TL (T790M/L858R) mice

  • Dosages

    25mg/kg

  • Administration

    Gavage

Customer Product Validation

Data from [Mol Cancer Ther, 2012, 11, 2149-57]

Data from [Lab Invest, 2011, 92, 371-383]

Data from [Lab Invest, 2011, 92, 371-383]

, , Dr. Yong-Weon Yi from Georgetown University Medical Center

Selleck's WZ4002 has been cited by 39 publications

ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors [ Cancer Metab, 2023, 11(1):20] PubMed: 37932830
MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state [ Cancer Gene Ther, 2022, 29(12):1878-1894] PubMed: 35840668
Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy [ Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w] PubMed: 33686255
Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER-Mitochondria Interface in Oncogene-Driven NSCLC [ Cancers (Basel), 2021, 13(16)4133] PubMed: 34439291
RAB31 marks and controls an ESCRT-independent exosome pathway [ Cell Res, 2020, 10.1038/s41422-020-00409-1] PubMed: 32958903
Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway [ Cancer Res, 2020, 80(21):4655-4667] PubMed: 32873635
Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines [ Cells, 2020, 9(12)E2596] PubMed: 33287368
HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. [ Nat Cell Biol, 2019, 21(8):1027-1040] PubMed: 31332347
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. [ Oncogene, 2019, 38(37):6399-6413] PubMed: 31324888
[ Front Pharmacol, 2019, ] PubMed: 31998131

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.